Sellas Life Sciences Group Inc (SLS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 03-2023 | 12-2022 | 09-2022 | 06-2022 | 03-2022 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -11,097 | -41,301 | -32,180 | -25,158 | -16,744 |
| Depreciation Amortization | N/A | N/A | 10,000 | 10,000 | 10,000 |
| Accounts receivable | N/A | N/A | N/A | N/A | -1,000 |
| Accounts payable and accrued liabilities | -284 | 1,213 | -17 | 1,195 | 667 |
| Other Working Capital | -1,655 | 5,641 | 2,074 | 1,447 | -837 |
| Other Operating Activity | 909 | 10,638 | 1,466 | -395 | 764 |
| Operating Cash Flow | $-12,127 | $-23,809 | $-18,657 | $-12,911 | $-7,150 |
| Cash Flows From Investing Activities | |||||
| Purchase Sale Intangibles | N/A | -4,500 | -4,500 | -4,500 | N/A |
| Other Investing Activity | 0 | -4,500 | -4,500 | -4,500 | 0 |
| Investing Cash Flow | $N/A | $-4,500 | $-4,500 | $-4,500 | $N/A |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 18,904 | 24,079 | 23,150 | 23,043 | 47 |
| Financing Cash Flow | $18,904 | $24,079 | $23,150 | $23,043 | $47 |
| Beginning Cash Position | 17,225 | 21,455 | 21,455 | 21,455 | 21,455 |
| End Cash Position | 24,002 | 17,225 | 21,448 | 27,087 | 14,352 |
| Net Cash Flow | $6,777 | $-4,230 | $-7 | $5,632 | $-7,103 |
| Free Cash Flow | |||||
| Operating Cash Flow | -12,127 | -23,809 | -18,657 | -12,911 | -7,150 |
| Free Cash Flow | -12,127 | -23,809 | -18,657 | -12,911 | -7,150 |